18:32 , Mar 8, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery; drug platforms

TECHNOLOGY: Viral vectors; gene therapy A Cas9 ortholog derived from Campylobacter jejuni could enable the use of AAV vectors to deliver CRISPR-based gene therapies. The 984-residue C. jejuni ortholog is smaller than the Cas9 enzymes from...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Company News

Benitec, Tacere deal

Benitec will acquire RNAi company Tacere for about 102.3 million newly issued ordinary shares, which the companies valued at about $1.5 million. The shares represent a 9.5% stake in Benitec. In 2006, Tacere received an...